In this issue: Two oral medications for relapsing-remitting MS in phase III development; antihypertensives find new uses; Ginkgo biloba does not prevent cognitive decline in elderly; and FDA Actions.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content